About Archer
Archer Pharmaceuticals, Inc. (Archer) was founded in 2008 and specializes in targeted drug discovery for Alzheimer’s disease. Led by Chief Executive Officer and Chief Scientific Officer Michael Mullan, M.B.B.S., Ph.D. and Chief Technical Officer and Associate Chief Scientific Officer Fiona Crawford, Ph.D., Archer was created based on the groundbreaking research conducted at the Roskamp Institute in Sarasota, Florida.
Included in this research is a Phase I/IIA human clinical trial, currently being conducted in partnership with the Trinity College Institute of Neuroscience in Dublin, Ireland. The human clinical trial is the first trial of its kind specifically designed to investigate the effects of ARC 029 on patients with Alzheimer’s disease. The trial, which began in 2006, suggests that ARC 029 is well-tolerated in Alzheimer’s disease patients. It is anticipated that ARC 029 will enter Archer’s directed U.S. clinical trials for Alzheimer’s disease in the fourth quarter of 2008.
Our Mission
Archer and its world-class team of researchers and scientists are committed to identifying quality therapeutics and using their uniquely pure focus to find a cure for Alzheimer’s disease.
Our Strategy
Armed with extensive experience in amyloid biology, the Archer team has a pipeline of products that specifically target amyloid accumulation. The Archer strategy is two-fold:
- To take existing drugs with known safety profiles into the clinic for the new indication, Alzheimer’s disease.
- To use these drugs and related drugs as templates for the development of new, more effective drugs.
Our Motivation
Currently there are approximately 5.2 million Americans of all ages who have Alzheimer’s disease, with approximately 13 percent of those persons of the age 65 and older. By 2050, the number of individuals age 65 and older with Alzheimer’s disease is expected to increase to a range of 11 million to 16 million (Alzheimer’s Association, 2008).
It is with these alarming statistics and the unmet demand for effective therapeutics, that Archer is committed to specializing in identifying new treatments for Alzheimer’s disease.
